Fitch affirms Boston Scientific

Fitch Ratings said it affirmed Boston Scientific Corp.'s ratings and stable outlook. following the announcement the company has reached a settlement under which it has agreed to pay its former partner, Medinol, Ltd., $750 million.

Affirmed ratings include the company's senior unsecured notes at A, $2.165 billion unsecured bank credit facility at A and commercial paper at F1.

Fitch noted the settlement amount was within expectations and the uncertainty, which surrounded the disputes, has been resolved, adding the cash settlement does not affect Boston Scientific's rating given the strength of the company's credit profile, cash flow generation and liquidity.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.